---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-026500"
form_type: "8-K"
ticker: "IMMX"
cik: "0001873835"
company_name: "Immix Biopharma, Inc."
filed_at: "2025-12-08T23:59:59+00:00"
generated_at: "2026-05-16T14:05:14.298400+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Immix Biopharma reports 75% CR rate in Phase 2 NXC-201 for AL amyloidosis, BLA plan 2026

## Summary
- NXC-201 achieved 75% complete response (15/20) by independent review committee in relapsed/refractory AL amyloidosis.
- MRD negativity in 4 of 5 pending patients suggests future CR rate could reach 95%.
- Organ responses observed in 70% of evaluable patients; no neurotoxicity and only low-grade CRS (median 1 day).
- NEXICART-2 final readout and BLA submission planned for 2026; therapy has FDA RMAT and orphan designations.
- Current standard-of-care CR rate in this setting is under 10%, highlighting high unmet need.

## SEC filing metadata
- accession: 0001493152-25-026500
- form_type: 8-K
- ticker: IMMX
- cik: 0001873835
- company_name: Immix Biopharma, Inc.
- filed_at: 2025-12-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1873835/000149315225026500/0001493152-25-026500-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1873835/000149315225026500/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-026500
- JSON: https://secwatch.observer/filing/0001493152-25-026500.json
- Plain text: https://secwatch.observer/filing/0001493152-25-026500.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.